Abstract: The object of the invention is a new Sheet Molding Compound (SMC), Thick Molding Compound (TMC), or Bulk Molding Compound (BMC) comprising at thermosetting resin on the basis of renewable resources with which molded parts can be produced in a molding process at elevated temperature and pressure said process being suitable to produce molded parts in an industrial process.

Abstract: The object of the invention is a new Sheet Molding Compound (SMC), Thick Molding Compound (TMC), or Bulk Molding Compound (BMC) comprising at thermosetting resin on the basis of renewable resources with which molded parts can be produced in a molding process at elevated temperature and pressure said process being suitable to produce molded parts in an industrial process

Abstract: The invention relates to a phantom for testing nuclear medicine instruments, such as for positron emission tomographs (PET), single-photon emission computed tomographs (SPECT) or even for autoradiography. The phantom contains a solid body that spontaneously emits gamma radiation or positrons. The disadvantages of a phantom filled with a radioactive liquid can be routinely overcome therewith. The inventive phantom can be produced with structuring smaller than 1 mm, and in particular even smaller than 0.1 mm. The inventive phantom can be used for the first time both for positron emission tomography (PET) and for autoradiography, since the phantom can emit both gamma radiation and positron radiation.

Abstract: This medicinal composition for the treatment and prevention of the symptoms of heart failure contains, by way of active principle, at least one compound chosen from 2-amino-1-(2,5-dimethoxyphenyl)-1-propanol (methoxamine) and its pharmaceutically acceptable salts, and it is presented in a form which can be administered by inhalation (aerosol or nebulizate).It was demonstrated, in particular, that the administration of methoxamine-HCl by inhalation, at a unit dosage of 10 mg, in the form of a 2% (w/v) solution in physiological saline, decreases airways resistance in subjects suffering from decompensated left ventricular failure, and increases the exertion tolerance of patients suffering from compensated left vetricular failure, whether the latter is of ischemic origin or otherwise.